Sofdra prescriptions and net revenue surged in Q4 FY26, with gross-to-net yield improving to 22%. Operating cash outflow dropped 54% as sales and cash reserves grew. Patent protection and a new API supplier position the company for continued growth and margin expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.